TP53 V218E

CI-VAR-00004504Explore in graph →CIViC 4657

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Pancreatic Neoplasm1
BRAF V600E AND ERBB2 Amplification AND SMAD4 LOSS AND TP53 V218E	Bevacizumab + Lapatinib + Trametinib + TrastuzumabCombination	Predictive	C	Supports Sensitivity Response	3	submitted	EID11712 In this clinical trial, 18 patients with pancreatic cancer were recruited. In this case, the patient (74 y/F) with pancreatic cancer harboring, BRAF V600E, SMAD4 Loss, ERBB2 amplification, and, TP53 V… (full text at CIViC) PMID 36670111 · Shaya et al., 2023 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.